SUMIT K. SUBUDHI to Immunotherapy
This is a "connection" page, showing publications SUMIT K. SUBUDHI has written about Immunotherapy.
Connection Strength
0.962
-
Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg? Curr Opin Urol. 2017 Nov; 27(6):566-571.
Score: 0.239
-
Immune checkpoint therapy-current perspectives and future directions. Cell. 2023 04 13; 186(8):1652-1669.
Score: 0.087
-
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 07; 9(7).
Score: 0.077
-
Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci. 2021 04; 1489(1):30-47.
Score: 0.074
-
Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell. 2019 Nov 14; 179(5):1177-1190.e13.
Score: 0.069
-
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019 10 29; 116(44):22246-22251.
Score: 0.069
-
Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. Eur Urol Focus. 2018 04; 4(3):442-454.
Score: 0.060
-
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589.
Score: 0.059
-
Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2017 02; 77(2):123-144.
Score: 0.056
-
Immune Checkpoint Therapies in Prostate Cancer. Cancer J. 2016 Mar-Apr; 22(2):117-20.
Score: 0.053
-
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014 Mar 05; 6(226):226ra32.
Score: 0.046
-
Improving the therapeutic benefits of ipilimumab. Oncology (Williston Park). 2010 Dec; 24(14):1288, 1294.
Score: 0.037
-
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022 02; 25(2):219-228.
Score: 0.019
-
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res. 2019 06 01; 25(11):3469-3470.
Score: 0.017